Skip to content

Evaluation of Stendo Pulsating Suit on Microcirculation and Central Blood Pressure in Essential Hypertension Patients

Evaluation of the Action of the Stendo Pulsating Suit on Peripheral Microcirculation and on Central Blood Pressure in Essential Hypertension Patients Treated But Not Stabilized

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02277821
Enrollment
24
Registered
2014-10-29
Start date
2014-10-31
Completion date
2015-07-31
Last updated
2015-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Keywords

Essential Hypertension, Central Blood Pressure, Microcirculation, Endothelium Stimulation

Brief summary

The action of one Stendo pulsating suit session will be evaluated on 24 patients referred to the hypertension consultations for essential hypertension treated but not stabilized. The effect of one Stendo pulsating suit session system will be mainly assessed on the peripheral cutaneous microcirculation and on the central arterial pressure.

Detailed description

The role of the endothelium in micro-vascular system is mediated by synthesis and release of numerous substances that act on the smooth muscle fibres. The release of these products is modulated, in turn, by various circulating molecules, by the autonomic nervous system and by local mechanical factors such as shear stress. The essential hypertension is associated to increased risks of cardiovascular and stroke morbidity and mortality and constitutes a major cause of severe kidney failure. The essential hypertension is a complex and multi-factorial disease; the dysfunction of the endothelium is of a great importance in the physiopathology of this disease, concerning both the consequences of the increase of the blood pressure and the possible cause of the hypertension development. The Stendo pulsating suit is expected to increase the cutaneous microcirculation measured by laser Doppler laser flowmetry and potentially to decrease the central blood pressure. Each patient will be his own witness and the clinical records will be assessed before, during when relevant, and after a pulsating suit session.

Interventions

DEVICEStendo pulsating suit System

The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).

Sponsors

Stendo
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patient referred to the Hypertension Hospital Consultation for essential hypertension treated but not stabilized * Patient with essential hypertension defined by a brachial arterial pressure of 140 ≤ Systolic Arterial Pressure \< 180 mm Hg and/or 90 ≤ Diastolic Arterial - Pressure \< 110 mm Hg * Essential Hypertension confirmed by an ambulatory measure of the arterial pressure during 24 hours before the pre-inclusion visit * Patients aged more than 40 and less than 70

Exclusion criteria

* Patient with secondary hypertension * Patient with diabetes * Patient with complete arrhythmia with atrial fibrillation * Patient with an advanced obstructive arterial disease * Patient with a recent and progressive deep venous thrombosis

Design outcomes

Primary

MeasureTime frameDescription
Peripheral microcirculation measured using Laser Doppler flowmetry35 minutes after the end of the Stendo session at D1 + 7 jours +/- 3Change in % of the peripheral cutaneous microcirculation using laser Doppler flowmetry after one Stendo pulsating suit session

Secondary

MeasureTime frameDescription
Humeral arterial pressure20 minutes after the end of Stendo session at D1 + 7 jours +/- 3Humeral arterial pressure using automatic measures with Dinamap device
Central blood pressureJust after the end of the Stendo session.at D1 + 7 jours +/- 3Central blood pressure measured by applanation using an applanation tonometry device; Central pulse pressure, Augmentation Index and subendocardial viability ratio will also be assessed.

Countries

France

Contacts

Primary ContactGuy AMAH, MD
guy.amah@lrb.aphp.fr+331 49 95 80 88

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026